CTOs on the Move

Sonora Quest

www.sonoraquest.com

 
Sonora Quest Laboratories operates 24 hours a day, 7 days a week, 365 days a year, providing our customers with a comprehensive menu of routine and specialty laboratory tests and services.
  • Number of Employees: 1K-5K
  • Annual Revenue: $250-500 Million

Executives

Name Title Contact Details
Eric Pickney
Senior Director of Enterprise Risk Management / Information Security Officer Profile

Similar Companies

Metaclin Research

Metaclin Research is a Austin, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Diagnostic Laboratories and Radiology

Diagnostic Laboratories and Radiology is a Burbank, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Open System Mri

Open System Mri is a Palm Desert, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Intelligent Retinal Imaging Systems

Intelligent Retinal Imaging Systems (IRIS) is the industry leader in early detection systems for diabetic eye disease. The company`s IRIS solution is an end-to-end FDA-cleared, telemedicine system that has improved quality, expanded access and reduced costs for diabetic retinopathy exams across the U.S.

Gritstone Oncology

Gritstone Oncology is a privately-held company headquartered in the San Francisco Bay Area with key functions located in Cambridge, Massachusetts and Pleasanton, California. We launched in October 2015, and since inception, have successfully raised two large, private financing rounds. We currently employ more than 60 professionals. We have brought together a group of distinguished scientific founders and advisors, a highly experienced and diverse leadership team and a seasoned and successful board of directors to tackle fundamental challenges at the intersection of cancer genomics and immunotherapy. With our unique approach to immuno-oncology, we are developing next-generation personalized immunotherapies to fight cancer in patients with the most difficult-to-treat tumors. We plan to combine these personalized neoantigen-targeted therapies with current immune checkpoint modulatory approaches to improve response rates and survival in patients with solid tumors.